Hospital or health organisation · founded 1891
Methodist Hospital
Omaha, United States · bestcare.org/methodist-hospital
- Citations, last 5 years
- 902
- Works, last 5 years
- 74
- h-index
- 81
- Scientists listed
- 0
- Grants since 2016
- 211
Grants received
2025–2030 · research · R24
Center for the Dissemination of Ultra-Long-Acting Antiretroviral Release Technology: DART Resource Program
Ying Xuan Chua · Methodist Hospital · funded by National Institutes of Health
2025–2027 · research · R21
Mechanisms of Resistance and Clinical Outcomes of non-Carbapenemase Producing Carbapenem-Resistant Klebsiella pneumoniae Infections
William R Miller · Methodist Hospital · funded by National Institutes of Health
2025–2027 · research · R21
Development of a stable mRNA prophylactic vaccine against SARS-CoV-2 omicron variant
Yongbin Liu · Methodist Hospital · funded by National Institutes of Health
2025–2029 · research · R01
Advancing Thyroid Cancer Diagnostics with AI-enhanced Multimodal Optical Histopathology
Xingde Li · Methodist Hospital · funded by National Institutes of Health
2025–2028 · research · R01
Clinical Impact of the Cefazolin Inoculum Effect
Cesar Augusto Arias · Methodist Hospital · funded by National Institutes of Health
2025–2028 · research · R01
Clinical Impact of the Cefazolin Inoculum Effect
Cesar Augusto Arias · Methodist Hospital · funded by National Institutes of Health
2025–2029 · research · R01
Regulation of innate immunity by self-adjuvated MRNA vaccines
Chinnaswamy Jagannath · Methodist Hospital · funded by National Institutes of Health
2024–2028 · research · R01
Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety
Prashant Dogra · Methodist Hospital · funded by National Institutes of Health
2024–2026 · research · R01
CAR T Cells for Advanced Thyroid Cancer
Moonsoo M. Jin · Methodist Hospital · funded by National Institutes of Health
2024–2026 · research · R21
Development of a pre-clinical syngeneic pig glioma model for research and translational studies
Philip J Horner · Methodist Hospital · funded by National Institutes of Health
2024 · research · R01
Administrative Supplement to Existing NIH Grant-Purchase of a Equipment
Kumar Pichumani · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis
Ming You · Methodist Hospital · funded by National Institutes of Health
2024–2025 · research · R56
Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disorders
Alireza Faridar · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy
Qing Yi · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity
Shu-Hsia Chen · Methodist Hospital · funded by National Institutes of Health
2024–2028 · research · R01
Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular Regeneration
Li Lai · Methodist Hospital · funded by National Institutes of Health
2024–2027 · research · R61
A multiplexed high-throughput platform to report pharmacologic alteration of cancer stem cell membrane potential and cell cycle state
Robert C Rostomily · Methodist Hospital · funded by National Institutes of Health
2024–2029 · training · T32
Antimicrobial Resistance Training Program in the Texas Medical Center (AMR-TPT)
Cesar Augusto Arias · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Natural Phenolic Compounds against Oral Candidiasis (OC)
Eleftherios Mylonakis · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Sirtuin -Dependent Regulation of Tuberculosis and HIV Interactions in Macrophages
Janice J Endsley · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy
Qing Yi · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis
Ming You · Methodist Hospital · funded by National Institutes of Health
2024–2029 · career development · K23
Pathogen and patient determinants of Candida gut colonization in critically ill patients
Max Wiener Adelman · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Functional roles of mTOR in tumor persistence
Yulin Li · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Novel gene delivery to modulate the tumor microenvironment and antigen-specific antitumor immunity
Shu-Hsia Chen · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy
Yong Lu · Methodist Hospital · funded by National Institutes of Health
2024–2029 · research · R01
Advancing Endovascular PAD Treatment: Overcoming Critical Knowledge Gaps with MRI-histology
Trisha Roy · Methodist Hospital · funded by National Institutes of Health
2023–2025 · research · R56
Microbiota-targeted approaches to resolve dysbiosis-induced AD neuropathology following brain injury.
Sonia Villapol · Methodist Hospital · funded by National Institutes of Health
2023–2030 · research · R01
4/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
Rafik Mark Ghobrial · Methodist Hospital · funded by National Institutes of Health
2023–2024 · research · R21
Emergence of TonB-dependent receptor mediated cefiderocol resistance among multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates.
William R Miller · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R35
Landscapes for Cell State Transition Leveraging by Single-Cell Multi-Omics
Guangyu Wang · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells
Qing Yi · Methodist Hospital · funded by National Institutes of Health
2023–2025 · research · R01
Improving transplantation access, equity and outcomes through responsive risk communication and support for living donor candidates with obesity.
Amy Doggette Waterman · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate
Francisco Altamirano · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Spinal Neuromodulation to Promote Physiologic and Molecular Plasticity in theInjured Spinal Cord
Philip J Horner · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
Andrei M Mikheev · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Clinical Impact of the Cefazolin Inoculum Effect
Cesar Augusto Arias · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Regulation of Cell Death in HIV Reservoirs
Jin Wang · Methodist Hospital · funded by National Institutes of Health
2023–2028 · research · R01
Role of lipid metabolism in CD8+ T cell ferroptosis
Qing Yi · Methodist Hospital · funded by National Institutes of Health
2023–2024 · research · R56
Flow, Fatty Acid Biosynthesis, and Hematopoiesis
Longhou Fang · Methodist Hospital · funded by National Institutes of Health